Steven DuBois, MD, MS

Dana-Farber Cancer Institute

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

49 more share only the name and are not shown

Trial papers in neuroblastoma

PubMed author-name match

Trials

Studies that name Steven DuBois, MD, MS as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:56 UTC. Open this list on ClinicalTrials.gov

N/A
NCT07793994 · Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors
Dana-Farber Cancer Institute · not yet recruiting · CNS Tumor, Solid Tumor, Relapsed Cancer · principal investigator
Ph1
NCT07027748 · Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Steven DuBois, MD · recruiting · Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 49 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name in neuroblastoma.